Adjuvant PIPAC in Gastric Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

October 1, 2022

Conditions
Gastric AdenocarcinomaGastric Cancer
Interventions
DRUG

Doxorubicin

Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.

DRUG

Cisplatin

Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.

Trial Locations (2)

5000

Odense PIPAC Center, Department of Surgery, Odense University Hospital, Odense

Unknown

Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Michael Bau Mortensen

OTHER

NCT04047004 - Adjuvant PIPAC in Gastric Cancer Patients | Biotech Hunter | Biotech Hunter